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Median follow-up in living patients was 38 months. One 
patient was lost from follow-up after 24 months. One patient 
treated with radiochemotherapy for a cT4a cN2b M0 
hypopharyngeal primary tumor was diagnosed with 
locoregional recurrence at 6 months of follow-up and 
deceased 3 weeks later. Due to renal insufficiency, he only 
received one cycle of cisplatin 100 mg/m² at day 1 of C-ART-
DPBN. There were no other locoregional or distant 
recurrences. A single other patient died due to a second 
primary lung carcinoma at 30 months after C-ART-DPBN. 
Actuarial LRC was 100%, 90%, 90% and 90% after 6, 12, 24 and 
36 months, respectively. Actuarial OS was 100%, 90%, 90% 
and 79% at 6, 12, 24 and 36 months, respectively.  
All grade 0-3 late xerostomia, dysphagia and mucosal 
integrity is shown in Figure 1. Grade 4 trismus was seen in 1 
patient at month 6, and reduced to grade 3 thereafter. One 
patient had a persistent skin ulcer upto 1 year of follow-up 
(scored as grade 4 skin necrosis) resulting from complete 
response of an involved neck node invading the skin; 
thereafter the wound healed spontaneously. There was no 
other grade 4 and no grade 5 late toxicity.  
Conclusions: Continuous adaptive radiotherapy using DPBN 
has been shown to be feasible and resulted in excellent 
locoregional control, survival and late toxicity. A multicentre 
prospective randomised trial is currently recruiting patients 
and will compare C-ART-DPBN to standard non-adaptive 
radiotherapy for head and neck cancer.  
   
EP-1150   
Accurate 3D mandibular VMAT dose prediction from 18-
FDG pet derived auto contours: streamlined ORN 
prophylaxis 
D. Rai1, J. Jackson1, M. Poulsen1, L. Anderson1, M. Gibson1, 
M.S. Kolsky2, M. Wada3 
1Gold Coast University Hospital, Radiation Oncology 
Queensland (ROQ), Gold Coast, Australia  
2Monash University, Department of Medical Imaging and 
Radiation Science, Melbourne, Australia  
3Austin Health, Radiation Oncology, Melbourne, Australia  
 
Purpose/Objective: Osteoradionecrosis (ORN) of the 
mandible is a feared late complication of high dose 
radiotherapy (RT) for head and neck cancer. ORN is often 
precipitated by extraction of carious teeth from a heavily 
irradiated mandible. The threshold dose, below which ORN 
does not occur is controversial, but generally believed to be 
above 60Gy in 2Gy per fraction. Many centres extract teeth 
prior to RT commencement to prevent ORN. Dental 
assessment, extractions and subsequent mandibular healing 
often delays RT simulation and start. This delay may affect 
tumour control. To minimise delay, efforts should be made to 
quickly and accurately identify areas of mandible at risk and 
focus assessment on the associated teeth, or completely 
bypass dental assessment. The aim of this study is to validate 
the accuracy of a rapid and objective 3D model for 
mandibular dose estimation that can be generated prior to 
patient simulation for RT. 
Materials and Methods: Ten consecutive patients treated 
definitively for mucosal squamous cell carcinoma (SCC) of the 
upper aero-digestive tract, with disease within 15mm of the 
mandible, were identified. All patients were treated over 35 
fractions to a maximum dose of 70Gy and had bilateral nodal 
irradiation to 56Gy using volumetric modulated arc therapy 
(VMAT). A PTV of 63Gy (biologically 60Gy in 30 fractions) was 
planned for each patient, consisting of a 10mm isotropic 
margin from GTV to CTV, and a further 5mm to PTV. Pinnacle 
9.6, was used to generate the auto-contoured MANDIBLE and 
a 63Gy DOSE structure, from the delivered plan. This dataset 
was imported into MIM 6.0, along with the patient’s PET and 
corresponding CT scan in RT position. The ‘PET Edge’ tool 
was used to auto-contour all primary tumours and upper 
cervical lymph nodes. A 15mm isotropic expansion was 
applied to create 63Gy MIM. The PET/CT was fused to the RT 
planning CT by MIM 6.0 The volume of overlap from the 
actual 63Gy DOSE and MANDIBLE, and 63gy MIM and MANDIBLE 
were recorded and compared using the Dice similarity 
coefficient (DSC).  
Results: All patients had stage IVa SCC. Nine patients had 
primaries of the oropharynx and one of the supraglottic 
larynx. Eight patients were male. The mean DSC of mandible 
between 63Gy DOSE and 63Gy MIM was 0.72. Sensitivity, 
specificity, positive and negative predictive values of the 
63Gy MIM model were 0.64, 0.98, 0.86 and 0.95 respectively. 
The mean and median volume of mandible receiving ≥63Gy 
was 6.4cc and 5.3cc respectively. 
Conclusions: Accurate dose prediction can be achieved using 
auto-contours from pre-therapy 18-FDG PET scans. Three-
dimensional visual displays of high mandibular dose may be 
useful for oral health practitioners to decide whether to 
prophylactically extract teeth. The volume of mandible 
receiving more than 63Gy is low, and the negative predictive 
value of this model is high. This suggests that the need for 
extraction may be relatively uncommon in centres using 
modern RT techniques. 
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Purpose/Objective: To evaluate long-term outcome in 
locoregionally advanced nasopharyngeal carcinoma (NPC) 
treated with Intensity-Modulated Radiotherapy-Simultaneous 
Integrated Boost (IMRT-SIB) and concurrent 
chemoradiotherapy (CHRT) +/- neoadjuvant chemotherapy 
(CHT). 
Materials and Methods: All patients (pts) were treated with 
IMRT-SIB (step and shoot techinque) and +/- neoadjuvant CHT 
(cisplatin - 5-fluorouracile or docetaxel+cisplatin+ 5-
fluorouracil every 21 days for 2 cycles) + concurrent CHRT 
(weekly cisplatin or cisplatin + 5-fluorouracil every 21 days). 
Computerized optimization was performed with fusion of MRI 
and/or PET with treatment planning CT images to accurately 
delineate the gross tumor volume (GTV), which included the 
primary disease and nodes greater than 1 cm in diameter or 
nodes with necrotic centers. The treated volumes and the 
dose delivered were as follows: Clinical Target Volume (CTV) 
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66-70 Gy : gross tumor volume + isotropic expansion of 5 mm 
; CTV 59.4-60 Gy: lymph node regions (LNR) at high risk; 
CTV50.4-54 Gy: LNR at low risk. PTV were developed by 
adding to CTV an isotropic expansion of 5 mm. Patients with 
II stage NPC were treated with concurrent CHRT and patient 
with III-IVA/B stage were treated with neoadjuvant CHT 
followed by concurrent CHRT. Acute and late toxicities were 
graded according to Radiation Therapy Oncology 
Group/European Organisation for Research and Treatment of 
Cancer radiation morbidity scoring criteria. 
Results: We retrospectively analyzed 53 patients (pts) with 
pathologically diagnosed NPC, including 37 males and 16 
females; mean age was 52.8 years (range 14-77 years). 
According to the AJCC 2010 staging system 8 pts had II stage, 
30 pts III stage and 15 pts IVA/B stage. At a median follow-up 
of 26 months, 13 pts experienced local regional failure and 
distant metastasis occurred in 11 pts. Reirradiation +/- 
chemotherapy were used as salvage treatment in 6 pts, 
chemotherapy in 2 pts and 2 other pts received surgery (in 1 
pt lymph node dissection and the other pulmonary 
metastasectomy). The 2 years actuarial loco-regional failure–
free survival and disease free survival were 78.9 % and 78.4 
%, respectively. No patients had treatment failure after 24 
months. 
 
 
No grade > 4 acute toxicity and no > 3 late toxicity were 
observed. 
Conclusions: IMRT- SIB combined with concurrent 
chemotherapy +/- neoadjuvant CHT resulted in encouraging 
rates of local regional control with acceptable rates of acute 
and late side effects in patients with locoregionally advanced 
NPC.  
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Purpose/Objective: To evaluate the efficacy and toxicity of 
induction chemotherapy (IC) followed by radiochemotherapy 
(RTCT) versus concurrent radiochemotherapy for 
locoregionally advanced nasopharyngeal cancer (NPC).  
Materials and Methods: Patients with locoregionally 
advanced NPC were treated with three cycles of induction 
chemotherapy (IC) with Taxotere (75 mg/m2) plus cisplatin 
(75 mg/m2), plus 5-Fluoruracil (750 mg/m2) followed by full 
doses of IMRT (70 Gy) concurrently with cisplatin 100 
mg/m(2) every 21 days for three cycles (Group A) or to the 
same RTCT regimen alone (Group B). The outcomes of 
patients was evaluated in terms of overall survival (OS), local 
control (LC), and toxicity. 
Results: From July 2007 until December 2013, 45 patients 
were analyzed. Among them, 23 patients received three 
cycles of IC and 22 patients were treated with concomitant 
radiochemotherapy alone. With a median follow-up of 63 
months for the entire group, (range 3-146), 1-ys, 3-ys and 5-
ys Overall Survival were 79%, 58% and 52% for patients 
treated with induction chemotherapy, and 95%, 89% and 81% 
for RTCT alone, respectively (p=0.04). One-year, 3-ys and 5-
ys Disease Free-Survival were 64%, 41% and 19% for patients 
undergone to IC, 88%, 81% and 65% for patients receiving 
RTCT alone (p=0.0020). Patients undergone to 
radiochemotherapy alone had a significantly higher local 
control than patients treated with IC (3-ys LC: 97% vs 40%: p= 
0.0014). The stage affect the final multivariate model for OS 
(p=0.03), and DFS (p=0.0021) and LC (p=0.0086). Acute 
toxicity was similar in both groups. 
Conclusions: Compared with the induction chemotherapy 
group, concurrent chemoradiotherapy alone could 
significantly improve prognosis in terms of overall survival, 
loco-regional failure-free survival, even if patients treated 
with neoadjuvant chemotherapy had a very locally advanced 
disease. However, distant metastatic events still remain a 
problem, and larger and multicenter randomized trials are 
required to assess whether IC followed by RTCT is superior to 
RTCT alone. 
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Purpose/Objective: Despite the numerous retrospective and 
prospective series about IMRT treatment of Nasopharyngeal 
Carcinoma (NPC) in the literature, there is not a clear 
consensus in dose schemes and target volume definitions. 
Furthermore, there are few studies about non-Asiatic 
populations, with small data on European countries. The aim 
of this study is to describe and analyze our results in treating 
all-stages NPC with IMRT-simultaneous integrated boost (SIB), 
in a non-endemic area.  
Materials and Methods: We performed a retrospective 
review of 52 consecutive patients with NPC treated with 
curative intention with IMRT-SIB in our institution between 
